How have VNDA shares performed in 2023?

Vanda Pharmaceuticals' stock was trading at $7.39 on January 1st, 2023. Since then, VNDA stock has decreased by 45.3% and is now trading at $4.04. View the best growth stocks for 2023 here .

Are investors shorting Vanda Pharmaceuticals?

Vanda Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 2,040,000 shares, an increase of 21.4% from the October 31st total of 1,680,000 shares. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio is presently 1.6 days. View Vanda Pharmaceuticals' Short Interest .

When is Vanda Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024. View our VNDA earnings forecast .

How were Vanda Pharmaceuticals' earnings last quarter?

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by $0.06. The biopharmaceutical company earned $70.10 million during the quarter, compared to analyst estimates of $73.50 million. Vanda Pharmaceuticals had a trailing twelve-month return on equity of 2.19% and a net margin of 5.56%. During the same period in the previous year, the firm posted $0.11 earnings per share.

What ETFs hold Vanda Pharmaceuticals' stock?

ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP) , Horizon Kinetics Medical ETF (MEDX) , iShares Neuroscience and Healthcare ETF (IBRN) , iShares U.S. Pharmaceuticals ETF (IHE) ,

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?

12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com . Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vanda Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN) , Zogenix (ZGNX) , Inovio Pharmaceuticals (INO) , NVIDIA (NVDA) , Gilead Sciences (GILD) , Exelixis (EXEL) , Sangamo Therapeutics (SGMO) , Array Technologies (ARRY) , Micron Technology (MU) and Novavax (NVAX) .

Who are Vanda Pharmaceuticals' major shareholders?

Vanda Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (3.04%), Jacobs Levy Equity Management Inc. (1.68%), Federated Hermes Inc. (1.57%), Charles Schwab Investment Management Inc. (1.12%), Ameriprise Financial Inc. (1.10%) and Northern Trust Corp (0.98%). Insiders that own company stock include Aranthan Jones II , Gunther Birznieks, Joakim Wijkstrom , Kevin Patrick Moran , Melissa Young, Mihael Hristos Polymeropoulos , Phaedra Chrousos , Richard W Dugan, Stephen Ray Mitchell , Thomas Watkins and Timothy Williams. View institutional ownership trends .

How do I buy shares of Vanda Pharmaceuticals?

Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Vanda Pharmaceuticals Stock Price, News & Analysis (NASDAQ:VNDA)

$4.04

+0.08 (+2.02%)

(As of 12/6/2023 ET)

Compare

Today's Range: $3.95
▼
$4.11
50-Day Range: $3.38
▼
$4.58
52-Week Range: $3.30
▼
$11.04

Volume: 652,518 shs
Average Volume: 790,740 shs
Market Capitalization: $232.43 million

P/E Ratio: 19.24
Dividend Yield: N/A
Price Target: N/A

Vanda Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
3.55% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.77
Upright™ Environmental Score
News Sentiment: 0.88
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.01) to ($0.46) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

385th out of 957 stocks

Biotechnology Industry

22nd out of 67 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Vanda Pharmaceuticals.

3.0

Short Interest

Percentage of Shares Shorted
3.55% of the outstanding shares of Vanda Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 1.6, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Vanda Pharmaceuticals has recently increased by 21.43%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Vanda Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Vanda Pharmaceuticals does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Vanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.
Environmental Sustainability
The Environmental Impact score for Vanda Pharmaceuticals is -1.77.

3.3

News and Social Media Coverage

News Sentiment
Vanda Pharmaceuticals has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.51 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Vanda Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 3 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
MarketBeat Follows
1 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vanda Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.70% of the stock of Vanda Pharmaceuticals is held by insiders.
Percentage Held by Institutions
97.92% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Vanda Pharmaceuticals are expected to decrease in the coming year, from ($0.01) to ($0.46) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vanda Pharmaceuticals is 19.24, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 120.28.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vanda Pharmaceuticals is 19.24, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 130.82.
Price to Book Value per Share Ratio
Vanda Pharmaceuticals has a P/B Ratio of 0.43. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vanda Pharmaceuticals Stock (NASDAQ:VNDA)

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

VNDA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VNDA Stock News Headlines

December 5, 2023 | bizjournals.com

D.C.'s Vanda Pharmaceuticals scores FDA review of key drug after multiyear battle

December 5, 2023 | finance.yahoo.com

Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug

December 7, 2023 | Edge On The Street (Ad)

Americans Now Favor Gold Over Stocks as an Investment Vehicle

Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.

December 4, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Announces that U.S. Food and Drug Administration Accepts New Drug Application for Tradipitant for the Treatment of Gastroparesis

December 3, 2023 | americanbankingnews.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Up 21.4% in November

November 11, 2023 | finance.yahoo.com

One Analyst Thinks Vanda Pharmaceuticals Inc.'s (NASDAQ:VNDA) Revenues Are Under Threat

November 10, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q3 2023 Earnings Call Transcript

November 9, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Announces Participation at November 2023 Investor Conferences

December 7, 2023 | Edge On The Street (Ad)

Americans Now Favor Gold Over Stocks as an Investment Vehicle

November 9, 2023 | finance.yahoo.com

Q3 2023 Vanda Pharmaceuticals Inc Earnings Call

November 8, 2023 | msn.com

Vanda Pharmaceuticals (VNDA) Reports Break-Even Earnings for Q3

November 8, 2023 | msn.com

Vanda Pharmaceuticals GAAP EPS of $0.00 beats by $0.04, revenue of $38.82M misses by $5.68M

November 8, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Reports Third Quarter 2023 Financial Results

November 8, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Inc (VNDA) Faces Revenue Decline Amid Generic Competition in Q3 2023

November 8, 2023 | markets.businessinsider.com

Vanda Pharmaceuticals earnings preview: what Wall Street is expecting

November 7, 2023 | msn.com

Vanda Pharmaceuticals Q3 Earnings Preview

November 1, 2023 | finance.yahoo.com

Vanda Pharmaceuticals to Announce Third Quarter 2023 Financial Results on November 8, 2023

October 20, 2023 | bizjournals.com

D.C.'s Vanda Pharmaceuticals to ask Supreme Court to review patent infringement lawsuit

October 20, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Intends to Petition the U.S. Supreme Court in its HETLIOZ® ANDA Litigation

October 16, 2023 | msn.com

Vanda Pharmaceuticals: Value In The Biotech Space

October 5, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Announces Participation in the Jefferies Inaugural Biotech CNS/Neuro Summit

September 22, 2023 | stocknews.com

Bionano Genomics (BNGO) Challengers: 3 Biotech Innovators to Buy Instead

September 5, 2023 | finance.yahoo.com

Why Shares of Vanda Pharmaceuticals Are Dropping on Tuesday

September 1, 2023 | finance.yahoo.com

5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects

September 1, 2023 | finance.yahoo.com

After Plunging -7.98% in 4 Weeks, Here's Why the Trend Might Reverse for Vanda (VNDA)

August 17, 2023 | fool.com

Vanda Pharmaceuticals (NASDAQ: VNDA)

August 1, 2023 | finance.yahoo.com

Earnings growth of 9.4% over 5 years hasn't been enough to translate into positive returns for Vanda Pharmaceuticals (NASDAQ:VNDA) shareholders

See More Headlines

Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/03/2021
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/14/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:VNDA
CUSIP: 92165910
CIK: 1347178
Web: www.vandapharma.com
Phone: (202) 734-3400
Fax: 202-296-1450
Employees: 290
Year Founded: 2002

Profitability

EPS (Most Recent Fiscal Year): $0.21
Trailing P/E Ratio: 19.24
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $6.28 million
Net Margins: 5.56%
Pretax Margin: 8.31%
Return on Equity: 2.19%
Return on Assets: 1.84%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.32
Quick Ratio: 6.31

Sales & Book Value

Annual Sales: $211.85 million
Price / Sales: 1.10
Cash Flow: $0.11 per share
Price / Cash Flow: 36.51
Book Value: $9.32 per share
Price / Book: 0.43

Miscellaneous

Outstanding Shares: 57,532,000
Free Float: 53,102,000
Market Cap: $232.43 million
Optionable: Optionable
Beta: 0.59

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Dr. Mihael H. Polymeropoulos M.D. (Age 63)
Founder, President, CEO & Chairman of The Board
Comp: $1.51M
Mr. Kevin Patrick Moran (Age 39)
Senior VP, CFO & Treasurer
Comp: $660.22k
Mr. Timothy Williams (Age 47)
Senior VP, General Counsel & Secretary
Comp: $724.38k
Mr. Joakim Wijkstrom (Age 57)
Senior VP & Chief Marketing Officer
Comp: $836.36k
Mr. Gunther Birznieks (Age 53)
Senior Vice President of Business Development
Comp: $690.83k
Mr. Scott L. Howell
Chief People Officer
Ms. Elizabeth Van Every
Head of Corporate Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VNDA Stock Analysis - Frequently Asked Questions

How have VNDA shares performed in 2023?: Vanda Pharmaceuticals' stock was trading at $7.39 on January 1st, 2023. Since then, VNDA stock has decreased by 45.3% and is now trading at $4.04.
View the best growth stocks for 2023 here.
Are investors shorting Vanda Pharmaceuticals?: Vanda Pharmaceuticals saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 2,040,000 shares, an increase of 21.4% from the October 31st total of 1,680,000 shares. Based on an average daily trading volume, of 1,300,000 shares, the days-to-cover ratio is presently 1.6 days.
View Vanda Pharmaceuticals' Short Interest.
When is Vanda Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 14th 2024.
View our VNDA earnings forecast.
How were Vanda Pharmaceuticals' earnings last quarter?: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) released its quarterly earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.20 by $0.06. The biopharmaceutical company earned $70.10 million during the quarter, compared to analyst estimates of $73.50 million. Vanda Pharmaceuticals had a trailing twelve-month return on equity of 2.19% and a net margin of 5.56%. During the same period in the previous year, the firm posted $0.11 earnings per share.
What ETFs hold Vanda Pharmaceuticals' stock?: ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Horizon Kinetics Medical ETF (MEDX), iShares Neuroscience and Healthcare ETF (IBRN), iShares U.S. Pharmaceuticals ETF (IHE),

What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?: 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Vanda Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).
Who are Vanda Pharmaceuticals' major shareholders?: Vanda Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Acadian Asset Management LLC (3.04%), Jacobs Levy Equity Management Inc. (1.68%), Federated Hermes Inc. (1.57%), Charles Schwab Investment Management Inc. (1.12%), Ameriprise Financial Inc. (1.10%) and Northern Trust Corp (0.98%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams.
View institutional ownership trends.
How do I buy shares of Vanda Pharmaceuticals?: Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:VNDA) was last updated on 12/7/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial